Lunai Bioworks (NASDAQ:LNAI) Stock Rating Upgraded by Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lunai Bioworks currently has a consensus rating of “Sell”.

Lunai Bioworks Stock Performance

NASDAQ:LNAI opened at $0.96 on Friday. The firm has a market capitalization of $22.49 million, a P/E ratio of -13.71 and a beta of 0.40. The company has a fifty day moving average of $1.08. Lunai Bioworks has a one year low of $0.81 and a one year high of $14.00.

Lunai Bioworks (NASDAQ:LNAI) last announced its earnings results on Friday, November 14th. The company reported $0.13 EPS for the quarter.

Institutional Trading of Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.